Cleerly ISCHEMIA vs FEops HEARTguide
AI Verdict
Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you need a non-invasive, AI-powered solution to assess the likelihood of coronary artery ischemia and characterize coronary plaque from CCTA scans. This tool is ideal for physicians seeking detailed, vessel-level insights into heart disease for personalized diagnosis, risk stratification, and treatment planning without invasive procedures.
View Cleerly ISCHEMIA →Choose FEops HEARTguide if…
Choose FEops HEARTguide if you require advanced pre-operative planning for structural heart procedures using predictive simulations and patient-specific digital twins. This platform is best suited for cardiologists and cardiothoracic surgeons aiming to optimize device sizing and positioning, evaluate potential outcomes, and enhance procedural success before entering the operating room.
View FEops HEARTguide →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly ISCHEMIA | FEops HEARTguide |
|---|---|---|
| Pricing | Contact for details | Unknown |
| Deployment | Web-based platform; data transfer via Cleerly Proxy (VPN or virtual appliance) | Cloud Based platform |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cleerly ISCHEMIACleerly ISCHEMIA (Tool A) offers integration with PowerScribe via API, a widely used radiology reporting system, which streamlines workflow for its target users. While both tools are web/cloud-based, this specific integration suggests a more optimized and efficient user experience within existing clinical environments.
Clinical Value
TieBoth tools are FDA-cleared and provide significant clinical value within their respective cardiology sub-specialties. Cleerly ISCHEMIA (Tool A) offers non-invasive ischemia detection and plaque characterization for coronary artery disease, while FEops HEARTguide (Tool B) provides predictive simulations for structural heart procedure planning. Their distinct applications address equally critical clinical needs, making a direct comparison of 'value' difficult.
Pricing & Value
TieBoth Cleerly ISCHEMIA (Tool A) and FEops HEARTguide (Tool B) require direct contact for pricing details, stating that pricing 'varies by provider' or is 'contact for pricing'. This lack of transparency prevents a meaningful head-to-head comparison of their pricing structures or overall value proposition.
Enterprise Readiness
Cleerly ISCHEMIACleerly ISCHEMIA (Tool A) explicitly states it has a Business Associate Agreement (BAA) and utilizes Cleerly Proxy (VPN or virtual appliance) for secure data transfer, demonstrating robust compliance and security measures. While FEops HEARTguide (Tool B) is HIPAA compliant and cloud-based, Tool A's specific mentions of BAA and secure data transfer methods indicate a higher level of demonstrated enterprise readiness.
Innovation
FEops HEARTguideFEops HEARTguide (Tool B) stands out with its 'digital twin technology' for patient-specific predictive simulations in structural heart procedures, offering a highly personalized and transformative approach to complex surgical planning. While Cleerly ISCHEMIA (Tool A)'s non-invasive FFR estimation is innovative, the digital twin concept for pre-operative planning represents a more disruptive application of AI.
Support & Docs
Cleerly ISCHEMIACleerly ISCHEMIA (Tool A) offers a dedicated 'Client Support' portal for existing users with specified operating hours (M-F, 10 am-6 pm ET) and a clear contact form, alongside extensive public-facing documentation. FEops HEARTguide (Tool B) provides general contact information and mentions support for specific technical setups, but lacks the same level of structured and transparent support resources.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly ISCHEMIA | FEops HEARTguide |
|---|---|---|
| Tool Name | Cleerly ISCHEMIA | FEops HEARTguide |
| Primary Purpose | Analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. | Cloud-based AI and digital twin platform for structural heart procedure planning, providing predictive simulations and anatomical measurements to optimize device sizing and positioning for improved patient outcomes. |
| Company | Cleerly | FEops NV |
| Tagline | AI-Powered Precision for Non-Invasive Ischemia Detection | Advancing personalized care in structural heart disease through predictive simulations. |
| Target Specialties | Cardiology, Radiology | Cardiology, Cardiothoracic Surgery |
| Key Functionality | AI-enabled CCTA analysis, Non-invasive fractional flow reserve (FFR) estimation, Vessel-level ischemia likelihood determination, Coronary plaque characterization. | Predictive simulation technology, AI-based anatomical measurements, Digital twin technology for patient-specific replicas, Evaluation of device sizing and positioning pre-operatively. |
Videos
Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and FEops HEARTguide.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly ISCHEMIA or FEops HEARTguide
Backers
Who funded each tool's parent company.